COMMUNIQUÉS West-GlobeNewswire

Kane Biotech Restarts Commercial Activities and Strengthens North American Management
12/02/2026
Company enters 2026 with renewed business momentum and key commercial appointments in the U.S. and Canada WINNIPEG, Manitoba, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or [...]
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
12/02/2026
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will [...]
Notice to the Annual General Meeting of Orion Corporation
12/02/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / NOTICE TO GENERAL MEETING 12 FEBRUARY 2026 at 12:05 EET Notice to the Annual General Meeting of Orion Corporation Notice is given to the shareholders of Orion Corporation of [...]
Catheter Precision, Inc. Secures up to $36.5 Million in Strategic Institutional Financing to Accelerate Growth
12/02/2026
VTAK has Agreed to Terminate its At-The-Market (“ATM”) Equity Offering Program Company Strengthens Balance Sheet and Aligns Institutional Capital for Long-Term Value Creation FORT MILL, S.C., Feb. 12, 2026 (GLOBE [...]
Velocity Clinical Research Appoints UK Medical Director
12/02/2026
DURHAM, N.C. , Feb. 12, 2026 (GLOBE NEWSWIRE) -- Velocity Clinical Research today announces the appointment of Dr. Ronnie Beboso as UK Medical Director, strengthening the organization’s medical leadership as it [...]
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
12/02/2026
PYRUKYND ® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full year AQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approval Company will have pre- [...]
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
12/02/2026
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo [...]
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
12/02/2026
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc . (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, [...]
NMD Pharma results from Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 selected for late-breaking oral presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
12/02/2026
Aarhus, Denmark, 12 February 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data results from its [...]
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
12/02/2026
Agency Feedback Provides Regulatory Clarity on Enrichment Strategy and Confirms CDR-SB as Sole Primary Endpoint for Registrational Development Boca Raton, FL, Feb. 12, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: [...]
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
12/02/2026
New company established by a leading international life sciences investment firm Tokyo, Japan and Cambridge, UK, 12 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announced that it has [...]
Vitaccess and Myasthenia Gravis Foundation of America form strategic partnership to advance generation of real-world evidence in MG
12/02/2026
Vitaccess and Myasthenia Gravis Foundation of America form strategic partnership to advance generation of real-world evidence in MG Boston, MA, USA and Oxford, UK – 12 February 2026 , Vitaccess, a leader in generating [...]
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
12/02/2026
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
12/02/2026
Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its [...]
Nicox confirme son éligibilité au PEA-PME
12/02/2026
Communiqué de presse Nicox confirme son éligibilité au PEA-PME 12 février 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), société [...]
Ipsen réalise de solides résultats en 2025, grâce à une performance soutenue de toutes les aires thérapeutiques, et annonce ses objectifs 2026
12/02/2026
Croissance des ventes totales du Groupe en 2025 de 10,9% à taux de change constant 1 (8,1% en données publiées), tirée par la croissance des trois aires thérapeutiques avec une croissance de 4,1% 1 en Oncologie, 102,5% [...]
Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission
12/02/2026
Oslo, 12 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results [...]
Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA
12/02/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 February 2026 – 7AM CET Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA Fagron, the [...]
Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial results
12/02/2026
Oslo, Norway, 12 th of February 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and preliminary results of 2025. Solid last quarter of 2025 signs-off a record year for Vistin [...]

Pages